Gregg L. Semenza
| Gregg L. Semenza | |
|---|---|
| Born | New York City |
| Institutions |
|
| Alma mater |
|
Gregg L. Semenza is a professor of pediatrics, radiation oncology, biological chemistry, medicine, and oncology at the Johns Hopkins University School of Medicine. He serves as the director of the vascular program at the Institute for Cell Engineering.[1] He is a 2016 recipient of the Lasker Award for Basic Medical Research.[2] He is best known for his discovery of HIF-1, which allows cancer cells to adapt to oxygen-poor environments.[3]
He studied beta thalassemia while doing his PhD at the University of Pennsylvania.[4]
Awards
- 2012, Elected to the Institute of Medicine
- 2012, Stanley J. Korsmeyer Award, American Society for Clinical Investigation
- 2008, Elected Member of the National Academy of Sciences
- 2008, Elected Member of the Association of American Physicians
- 2000, E. Mead Johnson Award for Research in Pediatrics, Society for Pediatric Research
- 1995 Elected Member of the American Society for Clinical Investigation
- 1989, Lucille P. Markey Scholar Award in Biomedical Science, Markey Trust
References
- ↑ http://www.hopkinsmedicine.org/profiles/results/directory/profile/0800056/gregg-semenza
- ↑ http://www.laskerfoundation.org/awards/show/oxygen-sensing-essential-process-survival/
- ↑ http://hub.jhu.edu/2016/09/13/gregg-semenza-wins-lasker-award/
- ↑ http://hub.jhu.edu/2016/09/13/gregg-semenza-wins-lasker-award/
This article is issued from Wikipedia - version of the 11/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.